171 related articles for article (PubMed ID: 38240716)
1. Aspirin-free antiplatelet strategies after percutaneous coronary interventions.
Capranzano P; Moliterno D; Capodanno D
Eur Heart J; 2024 Feb; 45(8):572-585. PubMed ID: 38240716
[TBL] [Abstract][Full Text] [Related]
2. P2Y
Capodanno D; Baber U; Bhatt DL; Collet JP; Dangas G; Franchi F; Gibson CM; Gwon HC; Kastrati A; Kimura T; Lemos PA; Lopes RD; Mehran R; O'Donoghue ML; Rao SV; Rollini F; Serruys PW; Steg PG; Storey RF; Valgimigli M; Vranckx P; Watanabe H; Windecker S; Angiolillo DJ
Nat Rev Cardiol; 2022 Dec; 19(12):829-844. PubMed ID: 35697777
[TBL] [Abstract][Full Text] [Related]
3. Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation.
Verheugt FWA; Huber K; Clemmensen P; Collet JP; Cuisset T; Andreotti F
Thromb Haemost; 2023 Feb; 123(2):159-165. PubMed ID: 36584699
[TBL] [Abstract][Full Text] [Related]
4. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
5. P2Y
Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
[TBL] [Abstract][Full Text] [Related]
6. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
[TBL] [Abstract][Full Text] [Related]
7. P2Y
Andò G; De Santis GA; Greco A; Pistelli L; Francaviglia B; Capodanno D; De Caterina R; Capranzano P
JACC Cardiovasc Interv; 2022 Nov; 15(22):2239-2249. PubMed ID: 36423966
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
Valgimigli M; Gragnano F; Branca M; Franzone A; da Costa BR; Baber U; Kimura T; Jang Y; Hahn JY; Zhao Q; Windecker S; Gibson CM; Watanabe H; Kim BK; Song YB; Zhu Y; Vranckx P; Mehta S; Ando K; Hong SJ; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Calabrò P; Jüni P; Mehran R;
JAMA Cardiol; 2024 May; 9(5):437-448. PubMed ID: 38506796
[TBL] [Abstract][Full Text] [Related]
9. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Wernly B; Rezar R; Gurbel P; Jung C
J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
[TBL] [Abstract][Full Text] [Related]
10. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
11. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
[TBL] [Abstract][Full Text] [Related]
12. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Wu XT; He RR; Liang SZ; Ye GY; Ding SB
Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of P2Y
Casula M; Casu G; Talanas G; Spano A; Tantry U; Bilotta F; Micheluzzi V; Merella P; Porcheddu T; Gorog DA; Bonaca M; Jeong YH; Farkouh ME; Kubica J; Isgender M; Gurbel PA; Navarese EP
Curr Probl Cardiol; 2024 Aug; 49(8):102635. PubMed ID: 38750991
[TBL] [Abstract][Full Text] [Related]
14. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
[TBL] [Abstract][Full Text] [Related]
15. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.
Ho MY; Chen PW; Feng WH; Su CH; Huang SW; Cheng CW; Yeh HI; Chen CP; Huang WC; Fang CC; Lin HW; Lin SH; Hsieh IC; Li YH
PLoS One; 2021; 16(5):e0251109. PubMed ID: 33979377
[TBL] [Abstract][Full Text] [Related]
16. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
Kuno T; Ueyama H; Takagi H; Bangalore S
Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
O'Donoghue ML; Murphy SA; Sabatine MS
Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
[TBL] [Abstract][Full Text] [Related]
18. P2Y
van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833
[TBL] [Abstract][Full Text] [Related]
19. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Alkhalil M; Džavík V; Bhatt DL; Mehran R; Mehta SR
Curr Cardiol Rep; 2022 Mar; 24(3):277-293. PubMed ID: 35294730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
